Literature DB >> 4037837

Regression in thin malignant melanoma. Microscopic diagnosis and prognostic importance.

P H Cooper, H J Wanebo, R W Hagar.   

Abstract

Forty-eight malignant melanomas of the extremities, 1 mm or less in maximal thickness, were studied to better define microscopic criteria of regression in thin melanomas. Eleven tumors (23%) exhibited definite regression in the form of one or more segmental areas (defects) where the invasive component was replaced by mononuclear cell infiltrate and fibrosis. Thirteen other tumors (27%) had diffuse, nonsegmental changes classified as probable regression. Nineteen lesions (40%) lacked regression, although 14 of these contained focal evidence of host response. Five melanomas (17% of lesions less than 0.75 mm thick) were equivocal for regression. There were no recurrences or metastases. The histologic diagnosis of regression in thin melanomas requires subjective judgments, but segmental defects represent a potentially reproducible criterion. Their width can be measured, and the proportion of the melanoma that has undergone regression can be estimated. The preponderance of data from the literature, supported by this study, indicates that regression has no prognostic importance in the vast majority of thin melanomas. There are observations, however, to suggest that in rare cases, regression may negate the prognostic value of microstaging of a thin melanoma. To date, the type and extent of such regressive changes have not been adequately defined.

Entities:  

Mesh:

Year:  1985        PMID: 4037837

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  13 in total

1.  The significance of inflammation and regression in melanoma.

Authors:  M G Cook
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

Review 2.  Regressing thin cutaneous malignant melanomas (< or = 1.0 mm) are associated with angiogenesis.

Authors:  R L Barnhill; M A Levy
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

3.  Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.

Authors:  Phyu P Aung; Priyadharsini Nagarajan; Victor G Prieto
Journal:  Lab Invest       Date:  2017-02-27       Impact factor: 5.662

4.  Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma.

Authors:  Susannah E McClain; Amber L Shada; Megan Barry; James W Patterson; Craig L Slingluff
Journal:  Melanoma Res       Date:  2012-08       Impact factor: 3.599

5.  Cutaneous melanomas exhibiting unusual biologic behavior.

Authors:  H M Shaw; J K Rivers; S W McCarthy; W H McCarthy
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

6.  [Regression in malignant melanoma. Definition, etiopathogenesis, morphology and differential diagnosis].

Authors:  B E Paredes
Journal:  Pathologe       Date:  2007-11       Impact factor: 1.011

7.  Changes in the presentation of nodular and superficial spreading melanomas over 35 years.

Authors:  Melanie A Warycha; Paul J Christos; Madhu Mazumdar; Farbod Darvishian; Richard L Shapiro; Russell S Berman; Anna C Pavlick; Alfred W Kopf; David Polsky; Iman Osman
Journal:  Cancer       Date:  2008-12-15       Impact factor: 6.860

8.  Immunohistochemical expression of C-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma.

Authors:  A C Lazaris; G E Theodoropoulos; K Aroni; A Saetta; P S Davaris
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

9.  Morphometric, DNA and PCNA in thin malignant melanomas.

Authors:  V Björnhagen; E Månsson-Brahme; J Lindholm; A Mattsson; G Auer
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

10.  Parotid melanoma of unknown primary.

Authors:  Jeffrey F Scott; Cheryl L Thompson; Ritva Vyas; Kord Honda; Chad Zender; Rod Rezaee; Pierre Lavertu; Henry Koon; Kevin D Cooper; Meg R Gerstenblith
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-13       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.